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Skeletal muscle has high energy requirement and alterations in metabolism are associated with 
pathological conditions causing muscle wasting and impaired regeneration. Congenital muscular 
dystrophy type 1A (MDC1A) is a severe muscle disorder caused by mutations in the LAMA2 gene. Leigh 
syndrome (LS) is a neurometabolic disease caused by mutations in genes related to mitochondrial 
function. Skeletal muscle is severely affected in both diseases and a common feature is muscle 
weakness that leads to hypotonia and respiratory problems. Here, we have investigated the 
bioenergetic profile in myogenic cells from MDC1A and LS patients. We found dysregulated expression 
of genes related to energy production, apoptosis and proteasome in myoblasts and myotubes. 
Moreover, impaired mitochondrial function and a compensatory upregulation of glycolysis were 
observed when monitored in real-time. Also, alterations in cell cycle populations in myoblasts and 
enhanced caspase-3 activity in myotubes were observed. Thus, we have for the first time demonstrated 
an impairment of the bioenergetic status in human MDC1A and LS muscle cells, which could contribute 
to cell cycle disturbance and increased apoptosis. Our findings suggest that skeletal muscle metabolism 
might be a promising pharmacological target in order to improve muscle function, energy efficiency and 
tissue maintenance of MDC1A and LS patients.
Skeletal muscle is the largest organ in the human body and is used to respond to a broad range of functional 
demands in each animal species. It represents approximately 50% of the total body weight and plays a central role 
in whole-body metabolism1. For normal function, skeletal muscle critically depends on mitochondrial ATP pro-
duction through oxidative phosphorylation (OXPHOS), which is fuelled by tricarboxylic acid cycle through glu-
cose/glycolysis, and fatty acids/β -oxidation2. Thus, in order to preserve muscle mass and prevent muscle atrophy 
it is important to maintain the energy balance3. Impairment of muscle function due to mitochondrial abnormali-
ties is linked to several pathological conditions such as cancer cachexia, obesity and ageing4–7, but mitochondrial 
function remains poorly characterized in muscular dystrophy6,8.
Congenital muscular dystrophy type 1A (MDC1A) is an autosomal recessive disorder caused by mutations in 
the human LAMA2 gene, encoding the α 2 subunit of laminin-2118. Severe hypotonia, progressive muscle weak-
ness and wasting, joint contractures, gravely impaired motor ability and respiratory failure characterize this dis-
order, which causes great difficulty in daily life and often leads to premature death8,9. A complex pathology is seen 
in MDC1A, which results from the dysregulation of many cellular mechanisms. Laminin α 2 chain is expressed 
in the basement membrane surrounding muscle fibres and is attached to muscle cells via integrin α 7β 1 and 
dystroglycan interactions. Consequently, absence or reduction of laminin α 2 chain leads to altered extracellular 
matrix expression and dysregulation of integrin α 7β 1 and dystroglycan-mediated signalling pathways8. Apart 
from this primary defect, several secondary manifestations such as increased apoptosis, enhanced proteasome 
and autophagic activity, extensive inflammation and pathological fibrosis have been identified10–14. Many of these 
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disease driving mechanisms have been targeted with success in mouse models for MDC1A10–14. Still, the clinical 
appliance of most of these approaches is years away8.
Leigh syndrome (LS), primarily described as a subacute necrotizing encephalomyelopathy in 1951, is a neu-
rometabolic disease caused by mutations in genes related to mitochondrial function15. LS has a prevalence of 1 
per 40,000 live births and is considered as the most common mitochondrial disease in children. The causes are 
heterogenic and more than 75 disease genes have been identified16. One group of mutations is associated with 
a lack-of-function of the OXPHOS complex IV, also called cytochrome c oxidase (COX). Mutations in SURF1 
(surfeit locus protein 1) are the most common cause of lack-of-function of COX in LS patients17,18. SURF1 is a 
nuclear-encoded small hydrophobic protein, localized to the mitochondrial inner membrane and involved in 
the initial assembly of the 13 subunits of the COX19. Patients with SURF1-associated LS (Surf1-LS) present neu-
rodevelopmental regression, hypotonia, spasticity, movement disorders (including chorea), cerebellar ataxia, and 
peripheral neuropathy17. Just like MDC1A, the prognosis of Surf1-LS is poor with a life expectancy reduced to 
only a few years17. Other common characteristics of the diseases include muscle weakness that leads to hypotonia 
and respiratory weakness, peripheral neuropathy, and epileptic seizures. Right now, there is no effective treatment 
available for either LS or MDC1A.
In order to unravel novel molecular mechanisms underlying MDC1A, we recently performed a quantitative 
proteomic analysis of affected muscles in the dy3K/dy3K mouse model of the disease20. A majority of the differen-
tially expressed proteins were found to be involved in various metabolic processes including glycolysis, fatty acid 
β -oxidation, tricarboxylic acid cycle, respiratory electron transport and oxidative phosphorylation. However, 
whether a similar metabolic crisis is detected in MDC1A patient cells remains unknown. More importantly, 
it has been demonstrated that loss of matrix attachment in epithelial cells leads to metabolic stress character-
ized by reduced nutrient uptake, decreased ATP production and increased levels of reactive oxygen species21. 
Therefore, we hypothesize that the extracellular matrix also regulates cellular metabolism in skeletal muscle cells 
and that laminin α 2 chain-detached skeletal muscle is metabolically compromised. Mitochondrial function has 
not been thoroughly studied in Surf1-LS muscle cells either, but considering the nature of underlying mutations, 
we expected that it would be altered. Conversely, increased apoptosis and enhanced proteasome activity have 
been identified as disease drivers in MDC1A11–13, but have not been studied in LS myogenic cells. Hence, we 
have here characterized apoptosis, proteasome activity and the bioenergetic profile in human muscle cells from 
MDC1A and Surf1-LS patients.
Results
Altered expression of metabolism-related genes in MDC1A and Surf1-LS muscle cells. We 
recently performed a proteomic analysis of skeletal muscle from the dy3K/dy3K mouse model of MDC1A and 
confirmed differential expression of selected proteins by other means. We found that a large portion of differen-
tially expressed proteins are involved in various metabolic processes20. To analyse if similar metabolic alterations 
are present in human, we analysed the expression of selected orthologue genes in muscle cells from MDC1A 
patients. In addition, we analysed muscle cells from Surf1-LS patients, which we hypothesized would have an 
altered metabolic gene expression profile. Genes related to glycolysis, tricarboxylic acid cycle, and respiratory 
electron transport/oxidative phosphorylation were analysed and included: PFK, encoding 6-phosphofruktoki-
nase; PYGM, encoding glycogen phosphorylase, muscle form; PGAM2, encoding phosphoglycerate mutase 2; 
PDHA1, encoding pyruvate dehydrogenase alpha1; IDH3, encoding isocitrate dehydrogenase 3; SDHA, encod-
ing succinate dehydrogenase complex flavoprotein subunit A; ATP5I, encoding ATP synthase, H+ transporting, 
mitochondrial F0 complex subunit E; NDUFS2, encoding NADH dehydroygenase (ubiquinone) Fe-S protein 
2; NDUFA8, encoding NADH:ubiquinone oxidoreductase subunit A8; PGC1α, encoding peroxisome prolifera-
tor-activated receptor gamma coactivator 1-alpha and finally ANT1, encoding adenine nucleotide translocator 1 
(for more details, see Table S1).
Expression of PFK, PYGM, IDH3, and ANT1 was significantly dysregulated in myoblasts from MDC1A and 
Surf1-LS patients compared to myoblasts from control subjects (Fig. 1A). Additionally, expression of PGAM2, 
SDHA and NDUFA8 was dysregulated in Surf1-LS myoblasts but remained unaltered in MDC1A myoblasts 
(Fig. 1A). Subsequently, PGAM2, PDHA1, SDHA and ANT1 were upregulated in both MDC1A and Surf1-LS 
myotubes (Fig. 1B).
Some genes, such as NDUFA8, PGC1α and ANT1 were similarly regulated in both proliferative and differ-
entiated stages, even though the differences in PGC1α expression were not statistically significant in myoblasts 
(Fig. 1A). In contrast, PDHA1 gene expression was not altered in MDC1A and Surf1-LS myoblasts but increased 
in corresponding myotubes (Fig. 1A and B).
There were also some genes whose expression was not coordinately regulated in MDC1A and Surf1-LS cells. 
One striking example is PGC1α, which was downregulated in MDC1A myoblasts and myotubes but upregulated 
in corresponding Surf1-LS cells. Another example is NDUFA8, which was only downregulated in Surf1-LS cells 
while its expression was not altered in MDC1A myogenic cells (Fig. 1A and B).
In summary, we show a dysregulated gene expression pattern of metabolism-related genes in MDC1A and 
Surf1-LS myogenic cells. Considering these results and previous proteomic data obtained from MDC1A mouse 
muscle, also demonstrating down- and upregulation of metabolism-related proteins, we hypothesise that meta-
bolic function should be altered in MDC1A and Surf1-LS myogenic cells.
Reduced mitochondrial respiration and ATP production in MDC1A and Surf1-LS muscle 
cells. In order to assess whether alterations in gene expression were accompanied by functional changes, we 
next experimentally analysed mitochondrial respiration in MDC1A and Surf1-LS myoblasts and myotubes from 
human patients. For this purpose, oxygen consumption rate (OCR, defined as the rate of change by which a cell 
consumes oxygen) was measured in real-time with injections of oligomycin, FCCP and rotenone in order to 
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inhibit ATP synthase, uncouple respiration and inhibit complex I of OXPHOS system, respectively22,23. Notably, 
we found significantly reduced OCR, which reflects decreased basal respiration, maximum respiration and ATP 
production in MDC1A and Surf1-LS myoblasts and myotubes compared with controls (Figs 2 A–D and 3 A–D). 
Spare respiration was also reduced in MDC1A and Surf1-LS myoblasts and in MDC1A myotubes (Figs 2E and 
3E). Non-mitochondrial respiration was decreased in MDC1A and Surf1-LS myoblasts but not in corresponding 
myotubes (Figs 2F and 3F) and coupling efficiency was also diminished in MDC1A myoblasts and in Surf1-LS 
myotubes (Figs 2G and 3G). Altogether, these data indicate that oxidative phosphorylation is severely impaired 
in MDC1A and Surf1-LS myogenic cells.
This impairment can be due to deficiencies in mitochondria content, reduced mitochondria function, or both. 
It is well known that mitochondrial biogenesis is controlled by nuclear genes, such as PGC1α24. In fact, PGC1α 
expression was reduced in MDC1A myotubes and increased in Surf1-LS myotubes, indicating that mitochondrial 
content could be different in the two cell types (Fig. 1A and B). Thus, we next measured the mtDNA content as 
it is an indicator of mitochondrial content25 and evaluated the integrity of the mitochondrial membrane. The 
relative mtDNA content was decreased in MDC1A and Surf1-LS myoblasts (Fig. 2H) and was accompanied by a 
Figure 1. Pattern of gene expression in MDC1A and Surf1-LS myogenic cells. Results represent differences 
in gene expression in human muscle cells (myoblasts (A) and myotubes (B) as indicated) among control 
subjects, MDC1A and Surf1-LS patient groups. For further details, see Methods section and Table S1. PFK: 
6-phosphofruktokinase; PYGM: glycogen phosphorylase, muscle form; PGAM2: phosphoglycerate mutase 2; 
PDHA1: pyruvate dehydrogenase alpha1; IDH3: isocitrate dehydrogenase 3; SDHA: succinate dehydrogenase 
complex flavoprotein subunit A; ATP5I: ATP synthase, H+ transporting, mitochondrial F0 complex subunit E; 
NDUFS2: NADH dehydroygenase (ubiquinone) Fe-S protein 2; NDUFA8: NADH:ubiquinone oxidoreductase 
subunit A8; PGC-1α: PPAR co-activator 1a; ANT1: adenine nucleotide translocator 1. Columns represent 
mean values and bars SE. Results are expressed as a fold change of controls. Statistical significance was assessed 
by one-way ANOVA followed by Duncan’s post hoc test. p < 0.05 values were considered as statistically 
significantly different from each other. Letters a, b and c were used to express the differences among groups and 
columns with the same letter are not significantly different.
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Figure 2. Impaired mitochondrial function in myoblasts from MDC1A and Surf1-LS patients. (A) OCR of 
control, MDC1A and Surf1-LS myoblasts in response to 5 μ M oligomycin, 1 μ M FCCP and 1 μ M rotenone. For 
further details see methods section. Decreased oxygen consumption was observed in MDC1A and Surf1-LS 
myoblasts compared to control cells. (B) Basal respiration; (C) Maximum Respiration; (D) ATP Production; (E) 
Spare respiration %; (F) Non-mitochondrial respiration; (G) Coupling efficiency. (H) Relative mtDNA content 
was decreased in MDC1A and Surf1-LS myoblasts compared to control cells. Results are expressed as a fold 
change of controls. (I) FACS measurement of Δ Ψ m using JC-1. Results are expressed as % cell population with 
normal Δ Ψ m. Columns represent mean values and bars SE. n = 3–10 biological replicates per patient and subject. 
Statistical significance was assessed by one-way ANOVA followed by Duncan’s post hoc test. p < 0.05 values 
were considered as statistically significantly different from each other. Letters a, b and c were used to express the 
differences among groups and columns with the same letter are not significantly different from another.
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Figure 3. Impaired mitochondrial function in myotubes from MDC1A and Surf1-LS patients. (A) OCR of 
control, MDC1A and Surf1-LS myotubes in response to 5 μ M oligomycin, 1 μ M FCCP and 1  μ M rotenone. For 
further details, see methods section. Decreased oxygen consumption was observed in MDC1A and Surf1-LS 
myotubes compared to control cells. (B) Basal respiration; (C) Maximum Respiration; (D) ATP Production; (E) 
Spare respiration %; (F) Non-mitochondrial respiration; (G) Coupling efficiency. (H) Relative mtDNA content 
was decreased in MDC1A and unaltered Surf1-LS myotubes compared to control cells. (I) FACS measurement 
of Δ Ψ m using JC-1. Results are expressed as % cell population with normal Δ Ψ m. (J) Mitochondrial function 
is restored by presence of laminin-211 in MDC1A myotubes. Columns represent mean values and bars SE. 
n = 3–10 biological replicates per patient and subject. Statistical significance was assessed by one-way ANOVA 
followed by Duncan’s post hoc test. p < 0.05 values were considered as statistically significantly different from 
each other. Letters a, b and c were used to express the differences among groups and columns with the same 
letter are not significantly different from another.
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slight reduction of the cell population with polarized mitochondria in MDC1A myoblasts, but this was not statis-
tically significant (Fig. 2I). In MDC1A myotubes, we found an approximate 40% reduction of the relative mtDNA 
content but noted normal mtDNA content in Surf1-LS myotubes (Fig. 3H). Similarly, mt-COX1 expression analy-
sis confirmed these results (Figure S1). Additionally, the percentage of cell population with normal mitochondrial 
membrane potential (Δ Ψ m) was reduced in MDC1A myotubes but not altered in Surf1-LS myotubes (Fig. 3I). 
In summary, these results indicate that absence of laminin α 2 chain leads to downregulated PGC1α expression, 
which impairs mitochondrial biogenesis, causing a reduction of mitochondrial content that finally leads to a bio-
energetic inefficiency in myoblasts and myotubes from MDC1A patients.
To confirm that the metabolic alterations were due to deficiency of laminin-211 in MDC1A cells, we cultured 
the MDC1A myotubes in plates coated with recombinant laminin-211 (Fig. 3J). Indeed, basal respiration, max-
imum respiration and ATP production as well as basal mitochondrial respiration and maximal mitochondrial 
respiration capacity were normalized to control levels in the presence of laminin-211 (Fig. 3J).
In Surf1-LS cells, on the other hand, the impaired OXPHOS system is related to mitochondria dysfunction, 
rather than deficiency in mitochondrial content and this mitochondria dysfunction cannot be overcome by the 
endogenously increased PGC1α expression.
Increased glycolysis in MDC1A and LS muscle cells. In order to quantify changes in the glycolytic 
metabolism, we next measured extracellular acidification rate (ECAR, defined as the rate of change in proton 
excretion from the cell) in real-time with injections of glucose, oligomycin and 2-DG (for more details, see meth-
ods section. Surprisingly, we found that ECAR was significantly higher in MDC1A myoblasts and myotubes com-
pared to control myogenic cells (Figs 4A and 5A). Likewise, ECAR was significantly higher in Surf1-LS myoblasts 
and myotubes compared to control cells (Figs 4A and 5A). Glycolysis, glycolytic capacity and glycolytic reserve 
were all significantly increased in MDC1A and Surf1-LS myogenic cells, whereas non-glycolytic acidification 
remained unchanged (Figs 4B–E and 5B–E). All in all, these data suggest that the impaired OXPHOS in MDC1A 
and Surf1-LS myogenic cells leads to an increased dependence on glycolysis for ATP production.
Reduced fatty acid oxidation in MDC1A and Surf1-LS muscle cells. In order to evaluate utiliza-
tion of external fatty acids (FA) in MDC1A and Surf1-LS muscle cells, we assessed OCR (after starving cells for 
12 h) just after adding palmitate to the media. Figure 6 shows decreased maximum mitochondrial respiration 
in MDC1A and Surf1-LS myotubes, compared with myotubes from control subjects indicating an impairment 
of exogenous FA uptake. Basal respiration and non-mitochondrial respiration were significantly decreased in 
Surf1-LS myotubes as well, and the same tendency was observed in MDC1A myotubes (Fig. 6). No difference was 
detected in MDC1A and Surf1-LS myoblasts (data not shown).
Disturbances in cell cycle population and apoptosis. Considering the altered metabolic profile in 
MDC1A and Surf1-LS muscle cells, we next analysed if the bioenergetic impairment could influence cell cycle 
populations, affecting cell proliferation, differentiation and viability. We analysed the cell cycle profile and quan-
tified the cell populations in MDC1A and Surf1-LS myoblasts and myotubes. Among all cell cycle phases (G0/
G1, S and G2/M), we observed increased S population in MDC1A and Surf1-LS myoblasts. A similar tendency 
was seen in myotubes, but the difference was not statistically significant (Fig. 7A). This profile was accompanied 
by an increased apoptotic cell population in MDC1A and Surf1-LS myotubes compared with control cells. These 
data indicate that disturbances in the cell cycle could be linked to impairment of cell differentiation, leading to 
apoptosis (Fig. 7A).
Increased apoptosis and proteasome activity in MDC1A and Leigh muscle cells. Caspase-3 
activation has been shown to be involved in impairment of satellite cell renewal and participate in apoptotic 
events during muscle repair in mitochondrial diseases26,27. Moreover, enhanced apoptosis and proteasome activ-
ity have been implicated in the pathology of MDC1A13,28. In order to confirm whether these events occurred 
in the muscle cells from MDC1A and Surf1-LS patients we assessed gene expression and enzymatic activity 
of caspase-3 and 20S proteasome. We observed an increased Caspase-3 mRNA expression in MDC1A and LS 
myoblasts and myotubes (Fig. 7B). Caspase-3 activity was concomitantly enhanced in MDC1A and Surf1-LS 
myotubes but not in corresponding myoblasts, indicating that the apoptotic events are present during the differ-
entiation process in these diseases (Fig. 7C). The mRNA expression of proteasome-related genes such as 20S core 
particle subunit α2 (PSMA2), MuRF1, MAFbx and USP19 was significantly augmented in MDC1A myoblasts and 
myotubes (Fig. 7B). Similarly, proteasome activity was escalated in MDC1A myoblasts and myotubes (Fig. 7D). 
The expression of some proteasome-related mRNAs was increased in Surf1-LS myoblasts and myotubes (Fig. 7B) 
but the activity of 20S proteasome was not significantly altered in myoblasts or myotubes from Surf1-LS patients 
(Fig. 7D). Conclusively, these data show that the MDC1A cells recapitulate pathological changes that have been 
reported previously, but that the proteasome activity is not enhanced in Surf1-LS muscle cells.
Discussion
A bioenergetic inefficiency can break the balance between anabolic and catabolic processes in skeletal muscle and 
lead to loss of muscle mass and muscle strength. Indeed, previous studies have described impaired metabolism in 
neuromuscular diseases29 but muscular dystrophies remain poorly characterized in this respect.
Our experimental data showed a dysregulated expression pattern of several genes related to metabolism in 
MDC1A and Surf1-LS muscle cells. We observed an increased expression of PGAM2 in myotubes of MDC1A 
and Surf1-LS patients, and PGAM2 encodes an enzyme involved in the energy generating phase of glycolysis. 
Okuda et al. observed that PGAM2 overexpression was related to decreased expression of glycolytic enzymes, 
alteration of metabolites involved in glycolysis and the tricarboxylic acid cycle, decreased mitochondrial res-
piration and increased mitochondrial ROS production in cardiomyocytes30. In fact, we observed a decreased 
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Figure 4. Increased glycolytic function in myoblasts from MDC1A and Surf1-LS patients. (A) ECAR of 
control, MDC1A and Surf1-LS myoblasts in response to 10 μ M glucose, 2.5 μ M oligomycin and 50 mM 2DDG. 
Increased extracellular acidification was observed in MDC1A and Surf1-LS myoblasts compared to control 
cells. (B) Glycolytic Capacity; (C) Glycolysis; (D) Glycolytic reserve; (E) Non-glycolytic acidification. For 
further details, see methods section. Columns represent mean values and bars SE. n = 10 biological replicates 
per patient and subject. Statistical significance was assessed by one-way ANOVA followed by Duncan’s post hoc 
test. p < 0.05 values were considered as statistically significantly different from each other. Letters a, b and c were 
used to express the differences among groups and columns with the same letter are not significantly different 
from another.
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PFK expression in MDC1A cells, and PFK encodes an important rate-limiting enzyme in glycolysis, upstream of 
PGAM2 activity. IDH3, a NAD+-dependent enzyme, is responsible for isocitrate conversion into α -ketoglutarate 
Figure 5. Increased glycolytic function in myotubes from MDC1A and Surf1-LS patients. (A) ECAR of 
control, MDC1A and Surf1-LS myotubes in response to 10 μ M glucose, 2.5 μ M oligomycin and 50 mM 2DDG. 
Increased extracellular acidification was observed in MDC1A and Surf1-LS myotubes compared to control 
cells. (B) Glycolytic Capacity; (C) Glycolysis; (D) Glycolytic reserve; (E) Non-glycolytic acidification. For 
further details, see methods section. Columns represent mean values and bars SE. n = 10 biological replicates 
per patient and subject. Statistical significance was assessed by one-way ANOVA followed by Duncan’s post hoc 
test. p < 0.05 values were considered as statistically significantly different from each other. Letters a, b and c were 
used to express the differences among groups and columns with the same letter are not significantly different 
from another.
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in the tricarboxylic acid cycle. IDH3 activity is stimulated by Ca2+, as well as by increased ADP/ATP and NAD+/
NADH concentration ratios, supporting its function in the oxidative direction of the tricarboxylic acid cycle31. 
In myoblasts, a 34% decreased expression of IDH3 was observed but no changes were observed in myotubes of 
MDC1A and Surf1-LS patients. Since IDH3 plays an important function in the oxidative direction of the Krebs 
cycle, the decreased IDH3 expression could indicate a change of metabolism in MDC1A and Surf1-LS myoblasts. 
Based on our previous proteomic studies20, we expected to find genes related to the OXPHOS system differentially 
expressed. In fact, a 20% reduced expression of NDUFS2 in MDC1A myotubes and a 30% reduction of NDUFA8 
expression in Surf1-LS myotubes was observed. NDUFS2 and NDUFA8 encode the NADH dehydroygenase 
Figure 6. Decreased FAO uptake in myotubes from MDC1A and Surf1-LS patients. (A) OCR of control, 
MDC1A and Surf1-LS myoblasts in response to 5 μ M oligomycin, 5 μ M, 1 μ M FCCP and 1 μ M rotenone. 
Decreased exogenous FA utilization was observed in MDC1A and Surf1-LS cells compared to control cells. For 
further details, see methods section. (B) Basal respiration; (C) Maximum Respiration; (D) ATP Production; 
(E) Spare respiration %; (F) Non-mitochondrial respiration; (G) Coupling efficiency. Columns represent mean 
values and bars SE. n = 3 biological replicates per patient and subject. Statistical significance was assessed 
by one-way ANOVA followed by Duncan’s post hoc test. p < 0.05 values were considered as statistically 
significantly different from each other. Letters a, b and c were used to express the differences among groups and 
columns with the same letter are not significantly different from another.
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Figure 7. Cell cycle, apoptotic and proteolytic profiles in MDC1A and Surf1-LS muscle cells. (A) Cell 
distribution in the different phases of the cell cycle. (B) Differences in gene expression of CASP3, PSMA2, 
MURF1, MAFBX and USP19 in MDC1A and Surf1-LS myoblasts and myotubes compared to control. (C) 
Caspase-3 enzymatic activity was increased in myotubes from MDC1A and Surf1-LS patients compared to 
control cells. (D) 20S proteasome enzymatic activity was increased in both myoblasts and myotubes from 
MDC1A patients but was unchanged in Surf1-LS muscle cells compared to control. Results are expressed as 
a fold change of controls. Columns represent mean values and bars SE. Statistical significance was assessed 
by one-way ANOVA followed by Duncan’s post hoc test. p < 0.05 values were considered as statistically 
significantly different from each other. Letters a, b and c were used to express the differences among groups and 
columns with the same letter are not significantly different from another.
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(ubiquinone) Fe-S protein 2 and NADH: ubiquinone oxidoreductase subunit A8, respectively. Both are parts of 
the nicotinamide adenine dinucleotide (NADH): ubiquinone oxidoreductase enzyme (complex I) of OXPHOS 
system. It is known that some cases of LS are related to deficiency of nuclear-encoded subunits of complex I32. 
Altogether, our data suggest that Surf1-deficiency could somehow influence not just only COX activity but also 
other OXPHOS complexes in human myogenic cells.
An increased ANT1 expression was observed in muscle cells from MDC1A and Surf1-LS patients. ANT1 is 
the predominant isoform present in skeletal muscle and although not normally included as a part of the OXPHOS 
system, it is a key protein regulating the mitochondrial ATP/ADP flux. It is known that there is a striking link 
between ANT1 and mitochondrial uncoupling in skeletal muscle, which refers to the dissociation of mitochon-
drial respiratory chain activity from ATP synthesis in OXPHOS, due to a proton leakage across the inner mito-
chondrial membrane33. It has been demonstrated that ANT1 is overexpressed in muscle of facioscapulohumeral 
muscular dystrophy (FSHD) patients34. FSHD is characterized by the adult onset of progressive weakness in 
muscles of the face, shoulders, feet and hips. FSHD patients show a significantly elevated ANT1 gene expression 
and increased amounts of ANT1 protein in skeletal muscle, resulting in mitochondrial dysfunction associated 
with increased oxidative stress35. Moreover, ANT1 expression is also enhanced in muscles from patients with 
Duchenne muscular dystrophy35 and has been shown to be correlated to mitochondrial alterations in atrophy 
caused by immobilization36 and cancer cachexia in vivo4. Altogether, our results may suggest that ANT1 overex-
pression could contribute to the bioenergetic impairment in both MDC1A and Surf1-LS muscle.
Another gene that we analysed was PGC1α, encoding a key nuclear receptor co-activator for mitochondrial 
biogenesis and formation/maintenance of slow twitch fibres in skeletal myocytes37. Here, we observed divergent 
results between MDC1A and Surf1-LS myogenic cells. A decreased expression of PGC1α was observed in myo-
blasts and myotubes from MDC1A patients, whereas we noted an increased expression in Surf1-LS myoblasts 
and myotubes. These results could be due to the different origin of the two diseases as MDC1A is an extracellular 
matrix-related disease whereas Surf1-LS is a mitochondrial disorder per se. Indeed, altered PGC1α expression can 
have distinct consequences in different pathological conditions. For example, overexpression of PGC1α in mice 
markedly decreased the ATP content in skeletal muscle and resulted in myopathy at 25 weeks of age, leading to 
muscle atrophy and lipid accumulation38. Moreover, an increased expression of PGC1α was observed in cancer 
cachectic animals and related to alterations in mitochondria morphology and function4,39. On the other hand, 
a decreased mitochondrial content, impaired mitochondria function and enhanced apoptotic susceptibility was 
observed in mice lacking PGC1α40. PGC1α is also related to protective effects on muscle mass under hindlimb 
unloading, preventing catabolism system activation in mice41. Some studies demonstrated increased PGC1α 
expression related to improvement of mitochondrial function in skeletal muscle of obese rats treated with poly-
unsaturated fatty acid42 and in dystrophin-deficient mdx muscle treated with the anti-diabetic drug metformin43. 
Our data corroborate the findings of Pullian et al., who observed a link between decreased COX activity and 
increased expression PGC1α in Surf1−/− mice, which can be a stress response in order to confer protective effects 
on cellular homoeostasis19. In fact, Viscomi et al.44 observed increased mitochondrial biogenesis and activities of 
OXPHOS components when PGC1α was overexpressed in Surf1−/− mice. In summary, our results confirm that 
PGC1α can be differentially expressed depending on the muscle disease.
Based on the gene expression profile, we hypothesized that the cellular bioenergetic system would be impaired 
in MDC1A and Surf1-LS myoblasts and myotubes. Indeed, when we assessed the function of the OXPHOS 
system and glycolysis in MDC1A and Surf1-LS cells, modulating those processes in real-time, we observed an 
energetic impairment of MDC1A and Surf1-LS muscle cells. Accordingly, the reduced mitochondrial function 
was accompanied by enhanced glycolytic activity. Moreover, a decrease of exogenous FA utilization in Surf1-LS 
myotubes was observed. All in all, these striking changes in metabolism were noted in both MDC1A and Surf1-LS 
and our results indicate that mitochondrial dysfunction would impair not only the skeletal muscle function but 
also interfere with the muscle regeneration and repair, since myoblasts are also bioenergetically impaired.
The bioenergetic inefficiency can be due to reduced mitochondria content, diminished mitochondria func-
tion, or both25. In fact, we observed a reduction of the relative mtDNA content in MDC1A myotubes, corroborat-
ing the PGC1α gene expression profile. On the other hand, relatively normal levels of mtDNA were observed in 
Surf1-LS myotubes, indicating that the impairment of the OXPHOS system is related to mitochondria dysfunc-
tion, rather than deficiency of mitochondrial content in Surf1-LS.
The consequences of mtDNA stability and content have been studied in some conditions like cancer45,46 and 
cardiomyopathies47. Furthermore, the therapeutic potential of increasing mtDNA content has been explored. For 
example, supplementation with butyrate in maternal diet was able to improve mtDNA content and increase mito-
chondrial activity in skeletal muscle from rat offspring48. Also, overexpression of PGC1α ameliorates muscular 
dystrophy in dystrophin-deficient mice49. Hence, it would be interesting to analyze if genetic or pharmacological 
approaches aimed at increasing mitochondrial biogenesis would have beneficial effects in MDC1A muscle.
The shift towards a high rate of glycolysis in MDC1A and Surf1-LS cells probably occurs in order to com-
pensate for the diminished energy production by impaired mitochondria. It is known that highly proliferative 
cells, such as cancer cells50 and in immune cells51 as well, generate ATP in an inefficient fashion, preferentially by 
utilizing glycolysis rather than oxidative phosphorylation. This phenomenon is described as the Warburg effect 
or aerobic glycolysis and it has been proposed to facilitate the uptake and incorporation of nutrients needed to 
produce a new cell50. In fact, we also observed a disturbance in the cell cycle population with an increased prolif-
erative state of MDC1A and Surf1-LS myoblasts, which confirms recent findings which associated proliferation 
of myoblasts in vitro with downregulation of OXPHOS and energy storage in ageing52. In addition, following 
differentiation we observed increased apoptosis in myotubes, confirming that bioenergetic impairment may lead 
to a disturbance in the cell cycle and late apoptosis in MDC1A and Surf1-LS.
Notably, apoptosis and the ubiquitin proteasome system play critical roles in the development of skeletal mus-
cle atrophy27,53. Increased caspase-3 gene expression and enzymatic activity in myotubes indicated that apoptotic 
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processes are part of muscle pathology in MDC1A, as previously described28 but shown for the first time for 
Surf1-LS. Also, increased gene expression of components of the ubiquitin-proteasome system and increased 
enzymatic activity of the 20S proteasome were observed in human MDC1A myoblasts and myotubes, confirming 
what was previously observed in muscle cells derived from one MDC1A foetus13. In Surf1-LS cells we observed 
increased gene expression of some components of the proteasome system, but this pattern did not reflect the 
enzymatic activity of the 20S-proteasome. These data indicate that proteolytic events are not part of the Surf1-LS 
pathology.
Although Surf1-LS and MDC1A myogenic cells from patients present energetic inefficiency, our data suggest 
that the molecular responses in these pathological conditions are different. The extracellular matrix (ECM) is 
known to provide physical support to tissues and organs and to maintain cell integrity and allow transduction 
of molecular signals, which have critical roles in tissues undergoing extensive mechanical stress, like skeletal 
muscle54. However, disturbances in ECM components, such as laminin-211, on fundamental aspects of mito-
chondrial biology have barely been studied before. The insight into abnormal mitochondrial function in MDC1A 
has come from studies of calcium handling and mitochondrial permeability transition pore opening. Treatment 
with an inhibitor of cyclophilin-D, which is a regulatory protein of the permeability transition pore, reduced 
muscular dystrophy pathology in laminin α 2 chain-deficient mice55. In addition, it is known that deficiency of 
collagen VI affects intracellular signalling pathways impairing the mitochondria function, leading to apoptosis 
in Col6a1−/− mice56 and other extracellular matrix proteins such as fibronectin and MMP-2 have been demon-
strated to influence mitochondrial function57. Here, we present the first evidence that laminin α 2 chain regulates 
PGC1α expression and mitochondrial content and that deficiency of mitochondrial content leads to bioenergetic 
impairment in MDC1A myogenic cells. Thus, it is becoming increasingly clear that a relationship exists between 
the extracellular matrix and mitochondria. However, it remains to be elucidated how these extracellular signals 
are transduced within muscle fibres.
Considering that LS is a neuropathology linked to mutations in genes encoding OXPHOS components16, 
it may not be surprising that metabolic function is affected in muscle. However, muscle cells from Surf1-LS 
patients have, to our knowledge, never been metabolically characterized. Our data suggest that the bioenergetic 
impairment triggers a response, such as increased PGC1α expression, in order to supply the energetic demand 
in Surf1-LS myoblasts. The increased PGC1α expression is maintained in myotubes but despite normalization of 
mitochondrial content, mitochondrial respiration remains compromised in Surf1-LS myotubes. Our results could 
in fact explain the symptoms of muscle weakness and hypotonia in Surf1-LS patients and are in agreement with a 
recent study, which demonstrated impaired metabolism in fibroblasts from LS patients with mtDNA mutations58. 
Pharmacological strategies such as treatment with antioxidants would be an interesting approach to improve 
mitochondrial function and to ameliorate the clinical features in Surf1-LS59,60.
In summary, our results suggest that in muscular pathological conditions, such as MDC1A and LS, an increase 
of glycolytic metabolism could be an attempt to compensate for the impairment of mitochondrial function in 
order to supply the energy demands of the cell. Since this scenario is not ideal for a tissue with high demand of 
energy production, such as skeletal muscle, this bioenergetic imbalance could cause cell cycle disturbance in 
myoblasts and increased apoptosis and proteolysis in myotubes. As a consequence, muscle degeneration and 
perhaps also the regenerative capacity61 could be affected, leading to muscle weakness and atrophy in MDC1A, 
and maybe in Surf1-LS as well (Fig. 8). The present study was performed with primary cells from patients, which 
is a limitation of our study due to senescence and the changing of molecular characteristics along cell passages62. 
Figure 8. Hypothetical contribution of bioenergetic impairment in MDC1A and Surf1-LS pathologies. 
Reduced mitochondrial function and enhanced glycolysis could contribute to cell cycle disturbances in 
myoblasts and increased apoptosis and proteolysis in myotubes. As a consequence, muscle maintenance would 
be compromised, leading to fibrosis and muscle atrophy.
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With the advent of immortalized cells from muscular diseases, such as MDC1A28, we hope that the molecular 
processes involved in this phenomenon can be clarified in the future. The bioenergetic impairment as a common 
denominator between MDC1A and Surf1-LS is an important finding in this study. Thus, independently of the 
underlying cause, metabolism may be a key system affected in diseases involving skeletal muscle. Moreover, our 
findings reinforce expert opinions that point out mitochondrial function and content as a key factor to maintain 
skeletal muscle homeostasis and function. Thus, a normal mitochondrial function reflects quality of life in health 
and constitute a promising target using pharmacological approaches in pathologies related to muscular dysfunc-
tion and atrophy5,7,53,63.
Methods
Human cells. Muscle primary cells from 3 MDC1A and 3 Surf1-LS patients and 3 normal subjects were 
provided by Muscle Tissue Culture Collection (MTCC) from University of Munich (http://www.klinikum.uni-
muenchen.de/Friedrich-Baur-Institut/de/forschung/muskelbank/, last accessed March 16, 2017). Cells were col-
lected and processed by MTCC in compliance with all applicable laws, rules, regulations and other requirements 
of any applicable governmental authority, including without limitation those applicable to patient informed 
consent64.
Cell culture. Myoblasts (passage numbers between 3 and 6) were cultured in Skeletal Muscle Growth Medium 
(Provitro) supplemented with 10% foetal bovine serum (Provitro) and kept in an incubator at 37 °C with 5% 
CO2. Differentiation was induced by treating cells with differentiation medium consisting of Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with GlutaMAX and 2% horse serum (all from Gibco®) for 7 days. The 
medium was changed every 2 days.
RNA and DNA extraction and real time-PCR analysis. RNA isolation was performed by using High 
Pure RNA Isolation Kit (Roche Diagnostics) according to manufacturer’s recommendations. First-strand cDNA 
was synthesized from total RNA (0.7 μ g) with oligonucleotide dT15 primers and random primers p(dN)6 by use 
of First Strand cDNA synthesis kit (Roche). Real time-PCRs were performed using Light Cycler 480 SYBR Green 
Master I (Roche) and were analysed by Light Cycler 480 SW 1.5 software (Roche). Oligonucleotide sequences 
used for PCR are listed in Table S1 indicating NCBI code. Primers were from Sigma (KiCqStart® SYBR® Green 
Primers) or designed using Primer3 software (http://primer3plus.com/cgi-bin/dev/primer3plus.cgi, last accessed 
March 16, 2017)65. Primer parameters were defined as follows: product size: 50–150 bp; primer size: 18–22 bp 
(opt: 20); primer Tm: 57–63 °C (opt: 60); primer GC%: 40–60%; maximum self-complementarity: 3–4. The 
Operon tool (http://www.operon.com/tools/oligo-analysis-tool.aspx, last accessed March 16, 2017) was utilized 
to check the putative primer-dimer formation. Amplification conditions consisted of 5 s of denaturation at 94 °C, 
9 s of annealing at 55–60 °C, and 9 s of extension at 72 °C for each step for 45 cycles. The relative amount of all 
mRNA was calculated using comparative CT method. Acidic Ribosomal Phosphoprotein P0 and GAPDH mRNA 
were used as the invariant controls for all studies66. Blast 2seq and Primerblast (NCBI: http://blast.ncbi.nlm.nih.
gov/Blast.cgi, last accessed March 16, 2017) were used to check if primers could be aligned with sequences of 
other organisms or could detect other genes. For measurement of mtDNA copy number, total DNA isolation was 
performed by using QIAamp® DNA Mini Kit (Qiagen). Real time-PCR conditions and primers for mtDNA anal-
ysis were performed according Venegas et al.67 and Lauritzen et al.47 with some modifications. β2-microglobulin 
gene was used as nuclear encoded gene for normalization of mtDNA content.
Real-time metabolic assays. Metabolic pathways were assessed using the Seahorse XFe96 Extracellular 
Flux Analyzer (Seahorse Bioscience). Cells were plated in XF96‐well cell culture microplate (V3-PS, Seahorse 
Bioscience), at a density of 5 × 104 cells per well for myoblasts and 8–12 × 103 cells per well for myotubes. 
Differentiation was induced by same procedure as described above. Seahorse plates were pre-coated with 
10 μ g/cm2 of collagen I (Sigma) diluted in ultra-pure water (Sigma). To access if mitochondrial function could 
be restored by presence of laminin, cells plates were coated with 2 μ g/cm2 of human rLaminin-211 (Biolamina) 
diluted in Ca2+/Mg2+ DPBS (Gibco), following the manufacturer’s instructions.
Cellular bioenergetics. To measure mitochondrial function cells were placed in unbuffered Basal Assay 
Medium (Seahorse) supplemented with 10 mM glucose, 1 mM glutamine and 2 mM sodium pyruvate, pH 7.4 
at 37 °C without CO2 for 1 h before the assay. Oxygen consumption rate (OCR) was monitored along time in 
repeated cycles of 3 minutes mix, 3 minutes measurement between injections of mitochondrial inhibitors (from 
Sigma): ATP synthase inhibitor oligomycin (final concentration: 5 μ M), proton ionophore fluorocarbonyl cya-
nide phenylhydrazone (FCCP: 1 μ M) and complex I inhibitor rotenone (1 μ M). Bioenergetic and mitochon-
drial function parameters such as basal respiration, maximal respiration, ATP production, spare respiration, 
non-mitochondrial respiration and coupling efficiency were analysed. All cell conditions were analysed as ten 
biological replicates per patient and data were pooled to give average values for each condition. After the assays, 
plates were saved and protein concentrations for each well were measured as described above. Data collection and 
analyses were performed using Wave software - Version 2.2 (Seahorse Bioscience).
Glycolytic function. At the day of experiment cells were placed in unbuffered Basal Assay Medium 
(Seahorse) supplemented with 1 mM glutamine pH 7.4 at 37 °C without CO2 for 1 h before the assay. Extracellular 
acidification rate (ECAR) was measured over time following injections of glucose (final concentration: 10 μ M) to 
activate glycolysis, oligomycin (2.5 μ M) to inhibit ATP synthase and 2-deoxy-D-glucose (50 mM) to inhibit gly-
colysis. Glycolytic function was analyzed based on parameters such as glycolytic capacity and reserve, glycolysis 
and non-glycolytic acidification.
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Fatty acid oxidation. To measure fatty acid oxidation (FAO) cell medium was changed one day before the 
assay to Substrate Limited Medium (DMEM (A14430–01-Gibco) supplemented with 0.5 mM glucose (Sigma), 
1 mM glutamax (Gibco), 0.5 mM L-Carnitine (Sigma) and 1% FBS (Sigma)). At the day of experiment cells were 
placed in FAO assay medium (111 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 2 mM MgSO4, 1.2 mM NaH2PO4) sup-
plemented with 2.5 mM glucose, 0.5 mM carnitine, and 5 mM HEPES, pH 7.4 at 37 °C. FAO assay was performed 
using XF Palmitate-BSA FAO Substrate (Seahorse Bioscience) according to manufacturer’s recommendations. 
Mitochondrial function was analyzed as described above with 3–7 biological replicates per patient and data were 
pooled to give average values for each condition.
Mitochondrial membrane potential (Δψm). Mitochondrial membrane potential (Δ ψ m) 
was determined using BD™ MitoScreen kit (Becton-Dickinson Biosciences). Briefly, cells were trypsin-
ized, harvested, and incubated with JC-1 (the cationic fluorescent dye probe 5,5′ ,6,6′ -tetrachloro-1,1′ ,3,3′ 
-tetraethylbenzimidazolcarbocyanine iodide) according to manufacturer’s specifications. The analysis of JC-1 
was performed on Becton Dickinson FACS LSR II SORP. JC1 was excited by 488 nm 100 mW Blue laser and 
detected on Alexa Fluor 488/FITC channel with 502LP dichroic mirror and 525/50 bandpass filter. Analysis was 
done on FACS diva software version 6.2. We present results as percentage of polarized mitochondria as functional 
mitochondria.
Protein extraction and quantification. For enzymatic assays, protein lysates were obtained at 4 °C by 
incubating cell pellets from myoblasts and myotubes in lysis buffer (50 mM HEPES pH 7.5, 5 mM EDTA pH 8, 
150 mM NaCl and 0.1% CHAPS) for 30 minutes with vortexing in 10 minutes intervals. Lysates were centrifuged 
at 13.000 rpm for 17 minutes at 4 °C. The protein concentrations were determined by method of the bicinchoninic 
acid with the commercial BCA™ Protein Assay kit (Thermo Scientific).
Cell cycle. The cell cycle phase distribution was determined using BD™ CycleTESTTM Plus DNA Reagent kit 
(Becton-Dickinson Biosciences) according to manufacturer’s instructions. The analysis of PI cell cycle was per-
formed on Becton Dickinson FACS Aria III. PI was excited by 561 nm 50 mW Yellow-Green Laser and detected 
on PI/PE-TxRed channel with 595LP dichroic mirror and 610/20 bandpass filter. Analysis was done on FACS diva 
software version 7.0.
Caspase-3 enzymatic assay. Caspase-3 activity was measured using the Caspase-3 Colorimetric 
Activity Assay Kit (Millipore). Protein samples were incubated for 1 h at 37 °C with Ac-DEVD-p-nitroaniline 
(DEVD-pNA) in assay buffer (provided in the kit) according to manufacturer’s instructions. Active caspase-3 
from the protein samples cleaves pNA from DEVD-pNA. The free pNA was quantified measuring the absorbance 
at 400 nm using a microplate reader (Wallac Victor 1420, Perkin Elmer).
20S Proteasome enzymatic assay. 20S proteasome activity was measured using the 20S 
Proteasome Activity Assay Kit (Millipore), which detects the chymotrypsin-like activity by monitoring 
amido-4-methylcoumarin (AMC) release from the synthetic peptide substrate LLVY-AMC. Protein samples 
were added to a black 96 well plate and incubated with Suc-LLVY-7-amino-4-methylcoumarin (LLVY-AMC) 
in assay buffer for 1 h at 37 °C according to manufacturer’s instructions. The free AMC peptide was measured 
by a fluorimeter (Wallac Victor 1420, Perkin Elmer) using an excitation wavelength of 380 nm excitation and an 
emission wavelength of 460 nm.
Statistical analysis. All data are shown as mean ± S.E.M. Levene test was used to assess the homogeneity of 
variances among groups. Statistical analysis of the data was performed by means of one-way analysis of variance 
(ANOVA) with Duncan post hoc test. For laminin-211 rescue experiment, t test was used to compare differences 
between myotubes from MDC1A patients with and without laminin-211 coating. p < 0.05 values were considered 
as statistically significantly different. Letters a, b and c were used to express the differences among groups and 
columns with the same letter are not statistically significantly different from each other. For each parameter, b 
and c represent a significant difference from control a; and c is used when Surf1-LS is significantly different from 
MDC1A and control groups.
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